Trial reportBlood2021
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Erratum issuedAbstract readClinical Trial, Phase IIILetter
In one paragraph
Trial report in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- Trial
- Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.Blood advances · 2022Trial
- A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.HemaSphere · 2026Article
- Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study.Blood research · 2025Article
- Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.HemaSphere · 2025Article
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.Annals of hematology · 2024Article
- Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions.Current oncology reports · 2024Review
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.Blood cancer journal · 2024Article
- Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies.Antibodies (Basel, Switzerland) · 2024Review
- Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study.HemaSphere · 2023Article
- Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.Blood cancer discovery · 2023Article
- Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.British journal of haematology · 2023Article
- Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma.Blood cancer journal · 2023Article
- Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients.Blood cancer journal · 2023Article
- High or low? Assessing disease risk in multiple myeloma.Hematology. American Society of Hematology. Education Program · 2022Article
- Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.Transplantation and cellular therapy · 2022Article
- NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.Cancers · 2022Article
- Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.Frontiers in oncology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
24 authors.
Ana Jiménez-UbietoCentro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00369, Hospital Universitario 12 de Octubre, Madrid, Spain.
Bruno PaivaClínica Universidad de Navarra, Centro de Información de Medicamentos (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC CB16/12/00369, Pamplona, Spain.ORCID 0000-0003-1977-3815
Noemi PuigHospital Universitario de Salamanca (IBSAL), Instituto de Biología Molecular y Celular del Cáncer (IBMCC)-Centro de Investigación del Cancer (CSIC), Salamanca, Spain.ORCID 0000-0001-7535-3861
Maria-Teresa CedenaCentro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00369, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0001-5851-3720
Joaquín Martínez-LópezCentro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00369, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0001-7908-0063
Albert OriolHospital Germans i Trials, Barcelona, Spain.ORCID 0000-0001-6804-2221
María-Jesús BlanchardHematology Department, Hospital Ramón y Cajal, Madrid, Spain.
Rafael RíosHospital Universitario Virgen de las Nieves de Granada, Granada, Spain.
Jesús MartinHospital Universitario Virgen del Rocío, Sevilla, Spain.
Rafael MartínezHospital Clínico San Carlos, Madrid, Spain.
Anna SuredaInstitut Catalá d'Oncologia-l'Hospitalet, Instituto de Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Miguel-Teodoro HernándezHospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.ORCID 0000-0002-6576-7881
Javier de la RubiaHospital La Fe, Valencia, Spain.ORCID 0000-0002-8354-768X
Isabel KrniskHospital Puerta de Hierro, Madrid, Spain.ORCID 0000-0002-2912-5072
Valentín CabañasHospital Virgen de la Arrixaca, El Palmar, Spain.ORCID 0000-0002-6248-2549
Luis PalomeraHospital Clínico Universitario Lozano Blesa, IIs Aragón, Zaragoza, Spain.
José María Sánchez-PinaCentro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00369, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-9181-0900
Joan BargayHospital Son Llatzer, Palma de Mallorca, Spain.
María-Victoria MateosHospital Universitario de Salamanca (IBSAL), Instituto de Biología Molecular y Celular del Cáncer (IBMCC)-Centro de Investigación del Cancer (CSIC), Salamanca, Spain.ORCID 0000-0003-2390-1218
Laura RosiñolHospital Clinic, Institut d'Investigacions Biomédiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; and.ORCID 0000-0002-2534-9239
Joan BladeHospital Clinic, Institut d'Investigacions Biomédiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; and.
Jesús San MiguelClínica Universidad de Navarra, Centro de Información de Medicamentos (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC CB16/12/00369, Pamplona, Spain.ORCID 0000-0002-9183-4857
Juan José LahuertaCentro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00369, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-3393-9570
GEM (Grupo Español de Mieloma)/PETHEMA (Programa Español de Tratamientos en Hematología) Cooperative Study Group
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneHumansInduction ChemotherapyLenalidomideMultiple MyelomaPrognosisProgression-Free SurvivalTransplantation, AutologousTreatment OutcomeBortezomibDexamethasoneLenalidomide
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.